Announcements Trials
Browse Landscape

Phase

Phase 1 24Phase 1/2 20Phase 2 13Phase NA 2Phase EARLY_PHASE1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Radiotherapy 17Specimen Handling 16Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11fludarabine 9Fluorodeoxyglucose F18 9X-Rays 8Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interleukin-2 × 1 year × Clear all
NCT06318871 2026-05-11

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
5 enrolled
Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡